RecruitingNCT06500494

To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment

Advanced Breast Cancer Patients Treated With Oral Vinorelbine: a Prospective and Retrospective, Observational Study - VINOREAL

Sponsor

Pierre Fabre Medicament

Enrollment

368 participants

Start Date

Sep 10, 2024

Study Type

OBSERVATIONAL

Conditions

Advanced Breast Cancer

Summary

This study looks at how well oral vinorelbine works in treating advanced breast cancer. It looks at women who have already had this treatment or are currently having it.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a real-world observational study describing how well oral vinorelbine (a chemotherapy drug taken by mouth) works in women with locally advanced or metastatic breast cancer who have been on this treatment for at least 2 years. **You may be eligible if...** - You are a woman aged 18 or older (19+ in Algeria) - You have been diagnosed with locally advanced or metastatic breast cancer - You started or are starting oral vinorelbine as part of your breast cancer treatment - You are willing to complete quality-of-life questionnaires (for those in the prospective cohort) **You may NOT be eligible if...** - There are no formal exclusion criteria listed for this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVinorelbine Tartrate Oral

The recommended dosage for oral vinorelbine is 60 mg/m² of body surface area (BSA) administered once weekly for the first three weeks, followed by 80 mg/m² of BSA for the following weekly administration.

Locations(3)

Centre Hospitalo-Universitaire Mustapha, Hopital Mustapha, Place du 1er Mai 1945, Sidi M'Hamed

Algiers, Algeria

Tianjing Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China

Azienda Ospedaliera San Gerardo U.O. Oncologia Medica

Monza, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06500494

Related Trials

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT042224132 locations

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

NCT0699702921 locations

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

NCT073188059 locations

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

NCT075243223 locations

A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer

NCT075405331 location